BioSpace News Archive

Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KYV-101 for the treatment of patients with refractory lupus nephritis (LN).

Karyopharm Therapeutics Inc. announced that the Company granted an aggregate of 44,600 restricted stock units to eight newly-hired employees.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 29,000 shares of Akebia’s common stock on May 31, 2023, as inducements material to such employee entering into employment with Akebia.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference.

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or “the Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the Jefferies Healthcare Conference taking place June 7-9, 2023, in New York, New York.

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced that members of the management team will participate in the following upcoming investor conferences.

CooperCompanies announced financial results for its fiscal second quarter ended April 30, 2023.

Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease

Immunocore Holdings Plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, announced that management will present at the following investor conferences in June: